Abstract PR012: Novel Strategy for RAS-pathway Targeting: Initial Results from a Phase 1b/2 Clinical Trial of the Oral HDAC Inhibitor Bocodepsin (OKI-179) Combined with Binimetinib in Patients with RAS-pathway Mutated Solid Tumors and NRAS-mutated Melanoma
Molecular Cancer Therapeutics（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined